BC Extra | Dec 10, 2019
Clinical News

Dec. 9 ASH Quick Takes: Kite, Principia, Blueprint, Precision and Rocket

Kite plans marketing applications for CD19 CAR T on pivotal MCL data  Kite Pharma Inc. reported a 93% best objective response rate including a 67% complete response rate -- secondary endpoints -- in 60 evaluable...
BC Innovations | Jul 25, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: June 2019

New Therapeutic Targets and Biomarkers: June 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in June. Therapeutic targets are defined as any protein, gene or other molecule...
BC Extra | Jun 21, 2019
Company News

June 20 Company Quick Takes: Priority Review for Alexion, Melinta therapies; plus Alimera, Denovo and more

Priority Review for Alexion's Ultomiris sBLA  FDA accepted and granted Priority Review to an sBLA from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) for Ultomiris ravulizumab-cwvz to block complement-mediated thrombotic microangiopathy in patients with atypical hemolytic uremic syndrome....
BC Extra | Jun 20, 2019
Company News

Gene therapy, vaccines in focus as Sanofi maps out priorities

As Sanofi continues to pull back from diabetes and cardiovascular diseases, the French pharma is turning toward gene therapy and intensifying its focus on vaccines and cancer ahead of this fall’s CEO change. The shift...
BC Innovations | Jun 11, 2019
Distillery Therapeutics

Inhibiting FANCM-TOP3A-RMI1 interaction for osteosarcoma, Lesch-Nyhan syndrome

DISEASE CATEGORY: Cancer; endocrine/metabolic INDICATION: Bone cancer; metabolic Cell culture studies suggest inhibiting the FANCM-TOP3A-RMI1 interaction could help treat osteosarcoma and Lesch-Nyhan syndrome. In two human osteosarcoma cell lines and a human telomerase reverse transcriptase...
BC Innovations | Jun 7, 2019
Targets & Mechanisms

Following PARP, ATR axis next in line to expand synthetic lethal drug class

Promising ASCO readouts suggest targets in the ATR pathway are lining up behind PARP as the next drivers of “synthetic lethal” cancer killing. Biomarker and combination strategies presented at the American Society of Clinical Oncology...
BC Innovations | Jul 24, 2018
Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Cell culture and mouse studies suggest inhibiting RAD52 could help treat FANCM-deficient colorectal cancer. In a FANCM-knockout human colorectal cancer cell line, an shRNA targeting RAD52 encoded in a retroviral or lentiviral...
BC Week In Review | Jul 20, 2018
Company News

PTC acquiring CNS gene therapy play Agilis

PTC Therapeutics Inc. (NASDAQ:PTCT) will acquire gene therapy company Agilis Biotherapeutics Inc. (Cambridge, Mass.), giving the rare disease company four products in development for CNS disorders. PTC will pay Agilis shareholders about $200 million up...
BC Extra | Jul 19, 2018
Company News

PTC acquiring CNS gene therapy play Agilis

PTC Therapeutics Inc. (NASDAQ:PTCT) will acquire gene therapy company Agilis Biotherapeutics Inc. (Cambridge, Mass.), giving the rare disease company four products in development for CNS disorders. PTC will pay Agilis shareholders about $200 million up...
BC Week In Review | Jan 19, 2018
Financial News

Pherecydes raises €8.7M series B

Anti-infectives company Pherecydes Pharma S.A. (Romainville, France) raised €8.7 million ($10.6 million) in a series B round led by new investor GO Capital on Jan. 16. New investors Omnes Capital and Fa Dièse and other...
Items per page:
1 - 10 of 134